Showing 8651-8660 of 9758 results for "".
- Dermeleve to Modify Program for Sampleshttps://practicaldermatology.com/news/Dermeleve-Modify-Program-Samples/2474651/Dermeleve will transition away from its auto-ship model and self-serve request program for samples, but will still offer samples directly to patients and to clinicians who choose to hole wholesale inventory, the company said in an email to partners. “To ensure your patients can still ‘try
- Dupilumab Improves Clinical and Immunologic Markers in NShttps://practicaldermatology.com/news/dupilumab-improves-clinical-and-immunologic-markers-in-ns/2474591/Results from a recent pilot study suggest an IL-4/IL-13 blockade with dupilumab significantly improved skin and immunologic abnormalities in patients with Netherton syndrome (NS).
- FDA Gives Nod to First Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fda-gives-nod-to-first-cell-based-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2474382/The U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (prademagene zamikeracel, pz-cel), making it the first cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The approval addresses a major unmet clinical nee
- RILECSU Study: Rilzabrutinib Effective for Symptoms in Hard-to-Treat Urticariahttps://practicaldermatology.com/news/rilecsu-trial-rilzabrutinib-eases-symptoms-in-hard-to-treat-urticaria/2474350/Rilzabrutinib significantly reduced itch and hives in adults with antihistamine-refractory chronic spontaneous urticaria (CSU), according to new phase 2 trial results published in JAMA Dermatology.
- Review Unpacks Safety Data in Psoriasis Trialshttps://practicaldermatology.com/news/review-unpacks-safety-data-in-psoriasis-trials/2474174/While clinical trials frequently emphasize efficacy, safety data often remain inconsistently analyzed and underreported, according to the authors of a new review in the Journal of Clinical and Aesthetic Dermatology.
- Kenvue’s Ricciardone Explains New Data on the Value of Teamwork in Moisturizers and Retinoidshttps://practicaldermatology.com/news/Kenvues-Ricciardone-Explains-New-Data-Value-Teamwork-Moisturizers-Retinoids/2474166/Data presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, supported the “full sandwich” moisturizer method for new retinoid users who may experience sensitivity from retinization during the skin acclimation period while also suggesting that Neutrogena® H
- Outpatient Palliative Care Results in More Positive Experience for HS Patientshttps://practicaldermatology.com/news/empathy-and-expertise-define-positive-palliative-care-experiences-for-hs-patients/2474029/Individuals with hidradenitis suppurativa (HS) who receive outpatient palliative care (PC) reported significant improvements in wellbeing, according to findings published in Archives of Dermatological Research.
- Bimekizumab Trials 'Raise the Bar' for HS, Dr. Vivian Shi Sayshttps://practicaldermatology.com/news/Bimekizumab-Trials-Raise-Bar-HS-Dr-Vivian-Shi-Says/2473933/More than half of hidradenitis suppurativa (HS) patients treated with bimekizumab (BIMZELX, UCB) had no draining tunnels (DTs) at 2 years, and 63.6% reported no or mild skin pain, compared to 10.0% at baseline, according to new data presented at the 2025 American Academy of Dermatology (AAD) Annu
- Report: Seborrheic Dermatitis Market Poised for Expansion through 2032https://practicaldermatology.com/news/report-seborrheic-dermatitis-market-poised-for-expansion-through-2032/2473856/The seborrheic dermatitis market has been projected to grow through 2032, according to a new report from Delveinsight. The expansion in market size coincides with the CAGR study, according to a press release. The report notes the recent approval of roflumilast foam 0.3% (ZORYVE, Arcutis) f
- Colloidal Oatmeal Moisturizer in Managing Skin Microbiota: Studyhttps://practicaldermatology.com/news/colloidal-oatmeal-moisturizer-in-managing-skin-microbiota-study/2471650/A new in vitro study suggests a moisturizer containing colloidal oatmeal, patented filaggrin technology, niacinamide, and tocopheryl acetate selectively inhibits the growth and adhesion of Staphylococcus aureus (S. aureus) while promoting Staphylococcus epidermidis